NanoEcho (NANECH) investor relations material

Executive summary

• Focus on clinical validation and commercialization of a novel diagnostic system for rectal cancer, addressing a significant unmet need for reliable lymph node assessment before surgery.

• First commercial sale achieved with a system delivered to Lund University for research, marking a key milestone.

• Proof of Concept (PoC) study in healthy volunteers completed initial phase; preparations underway for analysis and next phase on cancer patients.

• Strengthened IP portfolio with new design patents granted in Japan and the USA.

Financial highlights

• Net sales for Q1 2026 were 0 TSEK (0 TSEK Q1 2025); total operating income 290 TSEK (128 TSEK), mainly from rental income.

• Result after tax was -5,224 TSEK (-5,302 TSEK Q1 2025); EPS after dilution -0.01 SEK (-0.02 SEK).

• Cash flow from operations was -4,506 TSEK (-6,047 TSEK); cash and cash equivalents at period end 4,290 TSEK (12,398 TSEK).

• Equity at period end was 17,270 TSEK (24,897 TSEK); equity ratio 79% (87%).

• Rights issue raised 8,650 TSEK before costs, with 6,725 TSEK registered during the period.

Outlook and guidance

• Market approval application now planned for H2 2029, delayed due to lower-than-expected capital raise.

• Business plan revised with targeted cost savings and structural adjustments; additional financing options under evaluation.

• Continued focus on clinical validation and commercialization, with further funding sought via options and EU grants.